Phaseline

Companies › Minoryx Therapeutics

Minoryx Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Neurology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Leriglitazone
Peroxisome proliferator-activated receptor gamma agonist
PPARGPhase 3Cerebral Adrenoleukodystrophy (cALD)May 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05819866LeriglitazonePhase 3Cerebral Adrenoleukodystrophy (cALD)NeurologyMay 2027

Targets

PPARG (1)

Companies with the same targets

Zydus Therapeutics Flare Therapeutics Boryung Pharmaceutical Dong Wha Pharmaceutical Inventiva Pharma

Companies built like this

Bigespas JYAMS PET Research & Development Longboard Pharmaceuticals TriGemX Bio Zogenix

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.